We Cannot Say Biologic Therapy Is Not Useful in Patients With Short-Bowel Syndrome From Resections Related to Crohn’s Disease, nor Can We Conclude They Are of Value

Limketkai et al1 provided a glimpse into an infrequently studied group of patients, those with short-bowel syndrome and Crohn's disease. Because of their decreased absorptive surface and resultant diarrhea, they are excluded from studies of investigational agents—usually biologics. These patients generally have the worst disease as well, or they would not have had so much bowel resected! It is therefore an important question to ask as to whether biologic therapy is useful in these patients and does it lead to a reduction in subsequent intestinal resections?

https://ift.tt/2qLrAW1